ES2176307T3 - USE OF SUBSTRATE AND / OR DONOR OF NITRIC OXIDE SYNTHEASE, OR A NITRIC OXIDE INHIBITOR FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF UTERINE CONTRACTILITY DISORDERS. - Google Patents

USE OF SUBSTRATE AND / OR DONOR OF NITRIC OXIDE SYNTHEASE, OR A NITRIC OXIDE INHIBITOR FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF UTERINE CONTRACTILITY DISORDERS.

Info

Publication number
ES2176307T3
ES2176307T3 ES95900759T ES95900759T ES2176307T3 ES 2176307 T3 ES2176307 T3 ES 2176307T3 ES 95900759 T ES95900759 T ES 95900759T ES 95900759 T ES95900759 T ES 95900759T ES 2176307 T3 ES2176307 T3 ES 2176307T3
Authority
ES
Spain
Prior art keywords
nitric oxide
inhibitor
donor
uterine contractility
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900759T
Other languages
Spanish (es)
Inventor
Robert E Garfield
Chandra Yallampalli
Kristof Chwalisz
Radoslaw Bukowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2176307T3 publication Critical patent/ES2176307T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a beta -agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or in a combination of progesterone antagonist, an oxytocin or oxytocin analogue antagonist or prostaglandin.
ES95900759T 1993-11-16 1994-11-17 USE OF SUBSTRATE AND / OR DONOR OF NITRIC OXIDE SYNTHEASE, OR A NITRIC OXIDE INHIBITOR FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF UTERINE CONTRACTILITY DISORDERS. Expired - Lifetime ES2176307T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15249693A 1993-11-16 1993-11-16

Publications (1)

Publication Number Publication Date
ES2176307T3 true ES2176307T3 (en) 2002-12-01

Family

ID=22543178

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900759T Expired - Lifetime ES2176307T3 (en) 1993-11-16 1994-11-17 USE OF SUBSTRATE AND / OR DONOR OF NITRIC OXIDE SYNTHEASE, OR A NITRIC OXIDE INHIBITOR FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF UTERINE CONTRACTILITY DISORDERS.

Country Status (20)

Country Link
EP (1) EP0730448B1 (en)
JP (1) JP4015185B2 (en)
KR (2) KR100358319B1 (en)
CN (1) CN1108795C (en)
AT (1) ATE212833T1 (en)
AU (2) AU8144594A (en)
BR (1) BR9408067A (en)
CA (1) CA2176721A1 (en)
CZ (1) CZ291475B6 (en)
DE (1) DE69429823T2 (en)
DK (1) DK0730448T3 (en)
ES (1) ES2176307T3 (en)
FI (1) FI962109A (en)
HU (1) HUT74465A (en)
NO (1) NO961993L (en)
NZ (1) NZ276105A (en)
PL (1) PL178174B1 (en)
PT (1) PT730448E (en)
SK (1) SK63396A3 (en)
WO (1) WO1995013802A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
PL183461B1 (en) 1995-03-14 2002-06-28 Regents Board Of Use of nitrogen oxide doniors and/or nitrogen oxide inhibitors for controlling dilatability or expansibility of uterine cervix
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
IT1288123B1 (en) * 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
ITMI20002117A1 (en) * 2000-09-29 2002-03-29 Ibsa Inst Biochimique Sa USE OF SODIUM NITROPRUSSIATE IN OBSTETRICS AND GYNECOLOGY
FR2842108B1 (en) 2002-07-09 2008-05-02 Effik COMPOUNDS BASED ON HORMONE AND NITROGEN MONOXIDE AND THEIR USE IN OBSTETRICS AND GYNECOLOGY
TWI477276B (en) * 2008-04-28 2015-03-21 Repros Therapeutics Inc Antiprogestin dosing regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116685C (en) * 1992-07-01 1999-11-23 Naoki Yamazaki (-)-ritodrine

Also Published As

Publication number Publication date
FI962109A (en) 1996-07-15
JPH09505068A (en) 1997-05-20
FI962109A0 (en) 1996-05-17
CZ291475B6 (en) 2003-03-12
CN1135178A (en) 1996-11-06
AU732532B2 (en) 2001-04-26
CA2176721A1 (en) 1995-05-26
DK0730448T3 (en) 2002-04-22
WO1995013802A1 (en) 1995-05-26
ATE212833T1 (en) 2002-02-15
EP0730448A1 (en) 1996-09-11
CN1108795C (en) 2003-05-21
SK63396A3 (en) 1997-03-05
BR9408067A (en) 1996-12-24
KR960705560A (en) 1996-11-08
DE69429823D1 (en) 2002-03-21
HU9601299D0 (en) 1996-07-29
AU8144594A (en) 1995-06-06
HUT74465A (en) 1996-12-30
CZ139096A3 (en) 1996-10-16
NZ276105A (en) 2001-04-27
NO961993L (en) 1996-07-12
PL314465A1 (en) 1996-09-16
PT730448E (en) 2002-07-31
PL178174B1 (en) 2000-03-31
KR100358320B1 (en) 2003-01-24
JP4015185B2 (en) 2007-11-28
NO961993D0 (en) 1996-05-15
DE69429823T2 (en) 2002-08-22
EP0730448B1 (en) 2002-02-06
KR100358319B1 (en) 2002-10-25
AU8086398A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
ES2176307T3 (en) USE OF SUBSTRATE AND / OR DONOR OF NITRIC OXIDE SYNTHEASE, OR A NITRIC OXIDE INHIBITOR FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF UTERINE CONTRACTILITY DISORDERS.
GR3034165T3 (en) Combination of a progestational agent and a nitric oxide synthase substrate and/or donor for the treatment of preeclampsia and preterm labor
NO975128L (en) Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of uterine contraction disorders, preeclampsia, atherosclerotic vascular disease, hypertension and for hormone replacement therapy
NZ180042A (en) Mixture of corticosteroids:dermatoses treatment
ATE59960T1 (en) DELAYED RELEASE THEOPHYLLINE TABLETS.
GR3023312T3 (en) Therapeutically effective topical application of st1435.
NO971869L (en) Competitive progesterone antagonists for needs-oriented, female fertility control
IS4555A (en) Use of a nitric oxide donor or nitric oxide laxative to reduce cervical dilation and expansion
Corson et al. Intra-amniotic prostaglandin F 2alpha as a midtrimester abortifacient: effect of oxytocin and laminaria
Sammour Prostaglandins (PGS)
USD121864S (en) Design foe a elate or similar article
FR1489M (en) 4,4 'substituted diphenlysulfones and pharmaceutical preparations thereof for the treatment of viral diseases.
JPS5222746A (en) Ac load starting control device
JPS52136511A (en) Order waiting automatic camp-on connection system
王雪苔 The current situation and prospects of acupuncture
JPS5214228A (en) Conbustion system to restrain volume of emission of nitrogen oxide
Tiba Sands of Sanddunes in Kulun-buir
JPS523286A (en) High ceiling implement fitting device
ES85805U (en) New shopping bag (Machine-translation by Google Translate, not legally binding)
FR972356A (en) Improvement in reaction enamelling processes and furnaces, in particular by reduction
ES216711U (en) Perfected descapsulator. (Machine-translation by Google Translate, not legally binding)
CA580089A (en) Activation of clay by acid treatment, aging in inhibited oil, and calcination
JPS51135336A (en) Command retest control system
CA599704A (en) Unitary tank for either, the primary, or both the primary and secondary treatment of sewage
FR1547M (en) New drug, in particular for the treatment of hypophyseal follicle stimulating hyperactivity.